Eversept Partners, LP
13F Reported Value
ⓘ$1.9B
incl. option notional
Equity Holdings
ⓘ$1.5B
Option Notional
ⓘ$379.0M
$289.9M puts / $89.0M calls
Holdings
120
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Eversept Partners, LP disclosed 120 positions worth $1.9B in its Form 13F-HR for Q1 2026 — $1.5B in common stock plus $379.0M of put/call option positions (reported at underlying notional value, not premium at risk), led by $UTHR (UNITED THERAPEUTICS Corp) at 10.3% of the equity portfolio, followed by $QQQ and $ABVX. During the quarter the fund opened 42 new positions and exited 31 — including a new stake in $VRTX and a full exit from $DHR. The portfolio is most concentrated in Healthcare (90.3% of disclosed assets). All figures are sourced directly from Eversept Partners, LP’s Form 13F-HR filing with the SEC under CIK 1697013.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 80.1#46
Quality
$156.7M264,271 sh - $137.8M238,700 sh
- —
Quality
$104.0M934,423 sh - —
Quality
$98.5M1,785,175 sh - —
Quality
$87.4M2,173,286 sh - 46.4
Quality
$76.9M384,713 sh - —
Quality
$69.6M107,000 sh - 30.0
Quality
$67.4M2,885,622 sh - 13.2
Quality
$56.7M1,788,016 sh - —
Quality
$53.7M924,193 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 UNITED THERAPEUTICS Corp$UTHR | 80.1#46 | $156.7M | 264,271 |
 INVESCO QQQ TRUST, SERIES 1$QQQPUT | — | $137.8M | 238,700 |
 Abivax S.A.$ABVX | — | $104.0M | 934,423 |
 GSK plc$GSK | — | $98.5M | 1,785,175 |
 Vera Therapeutics, Inc.$VERA | — | $87.4M | 2,173,286 |
 Natera, Inc.$NTRA | 46.4 | $76.9M | 384,713 |
 SPDR S&P 500 ETF TRUST$SPYPUT | — | $69.6M | 107,000 |
 Syndax Pharmaceuticals Inc$SNDX | 30.0 | $67.4M | 2,885,622 |
 Celldex Therapeutics, Inc.$CLDX | 13.2 | $56.7M | 1,788,016 |
 Vaxcyte, Inc.$PCVX | — | $53.7M | 924,193 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Eversept Partners, LP's 120 positions.
Showing top 10 of 120 holdings.
Sector Allocation
Healthcare
$1.4B
Real Estate
$106.9M
Technology
$35.0M
Industrials
$4.3M
Financials
$510,128
Full Holdings — Eversept Partners, LP (Q1 2026)
All 120 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $UTHR | UNITED THERAPEUTICS Corp | $156.7M | 10.3% | +5% | 80.1 |
| 2 | $QQQPUT | INVESCO QQQ TRUST, SERIES 1 | $137.8M | — | +6% | — |
| 3 | $ABVX | Abivax S.A. | $104.0M | 6.9% | +42% | — |
| 4 | $GSK | GSK plc | $98.5M | 6.5% | -33% | — |
| 5 | $VERA | Vera Therapeutics, Inc. | $87.4M | 5.8% | -29% | — |
| 6 | $NTRA | Natera, Inc. | $76.9M | 5.1% | +15% | 46.4 |
| 7 | $SPYPUT | SPDR S&P 500 ETF TRUST | $69.6M | — | +138% | — |
| 8 | $SNDX | Syndax Pharmaceuticals Inc | $67.4M | 4.4% | -13% | 30 |
| 9 | $CLDX | Celldex Therapeutics, Inc. | $56.7M | 3.7% | +25% | 13.2 |
| 10 | $PCVX | Vaxcyte, Inc. | $53.7M | 3.5% | -23% | — |
| 11 |  $BKD | Brookdale Senior Living Inc. | $48.8M | 3.2% | +852% | 43.1 |
| 12 |  $IONS | IONIS PHARMACEUTICALS INC | $47.5M | 3.1% | +17% | 37.1 |
| 13 |  $VRTXCALL | VERTEX PHARMACEUTICALS INC / MA | $40.2M | — | NEW | 76.6 |
| 14 |  $HCA | HCA Healthcare, Inc. | $37.5M | 2.5% | -17% | 70.5 |
| 15 | — | ISHARES TR | $37.2M | — | +86% | — |
| 16 |  $WELL | WELLTOWER INC. | $35.8M | 2.4% | NEW | 75.7 |
| 17 |  $DOC | HEALTHPEAK PROPERTIES, INC. | $32.5M | 2.1% | NEW | 62 |
| 18 |  $PODD | INSULET CORP | $30.1M | 2.0% | +92% | 70.4 |
| 19 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $28.9M | 1.9% | +2% | 37.2 |
| 20 |  $GERN | GERON CORP | $28.1M | 1.9% | +7% | — |
| 21 |  $OHI | OMEGA HEALTHCARE INVESTORS INC | $25.7M | 1.7% | NEW | 63.2 |
| 22 |  $LQDA | Liquidia Corp | $25.6M | 1.7% | +33% | 37.4 |
| 23 |  $CYH | COMMUNITY HEALTH SYSTEMS INC | $25.5M | 1.7% | +9% | 53.4 |
| 24 |  $AVTR | Avantor, Inc. | $23.3M | 1.5% | -6% | 38.4 |
| 25 |  $QGEN | QIAGEN N.V. | $21.8M | 1.4% | NEW | — |
| 26 | $QGENCALL | QIAGEN N.V. | $19.1M | — | NEW | — |
| 27 |  $EHC | Encompass Health Corp | $18.8M | 1.2% | +82% | 68.9 |
| 28 |  $LLY | ELI LILLY & Co | $17.5M | 1.1% | +79% | 89.3 |
| 29 |  $TVTX | Travere Therapeutics, Inc. | $16.1M | 1.1% | -54% | 39.2 |
| 30 |  $INSMCALL | INSMED Inc | $15.4M | — | NEW | 29.4 |
| 31 |  $CTMX | CytomX Therapeutics, Inc. | $15.0M | 1.0% | +27% | 19.1 |
| 32 | — | ISHARES TR | $14.3M | — | -22% | — |
| 33 |  $RGEN | REPLIGEN CORP | $14.2M | 0.9% | NEW | 54.1 |
| 34 |  $BBNX | Beta Bionics, Inc. | $14.2M | 0.9% | +109% | 22.8 |
| 35 |  $VRDN | Viridian Therapeutics, Inc.\DE | $14.0M | 0.9% | -60% | 30.5 |
| 36 |  $ARQT | Arcutis Biotherapeutics, Inc. | $13.6M | 0.9% | +33% | 41.2 |
| 37 |  $ARDX | ARDELYX, INC. | $13.4M | 0.9% | +30% | 35.3 |
| 38 |  $LTC | LTC PROPERTIES INC | $11.9M | 0.8% | NEW | 58.4 |
| 39 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $11.7M | 0.8% | +122% | 74.1 |
| 40 |  $CHE | CHEMED CORP | $11.7M | 0.8% | NEW | 67.2 |
| 41 |  $PHVS | Pharvaris N.V. | $11.5M | 0.8% | -7% | — |
| 42 |  $UNHCALL | UNITEDHEALTH GROUP INC | $10.8M | — | NEW | 66.8 |
| 43 | — | ISHARES TR | $9.9M | — | -83% | — |
| 44 |  $PNTG | Pennant Group, Inc. | $9.5M | 0.6% | +6% | 56.4 |
| 45 | — | SELECT SECTOR SPDR TR | $9.3M | — | NEW | — |
| 46 |  $NAMS | NewAmsterdam Pharma Co N.V. | $9.1M | 0.6% | -32% | — |
| 47 |  $PALI | PALISADE BIO, INC. | $8.7M | 0.6% | -7% | — |
| 48 |  $MRNA | Moderna, Inc. | $8.1M | 0.5% | -40% | 15.9 |
| 49 |  $VKTX | Viking Therapeutics, Inc. | $7.8M | 0.5% | NEW | — |
| 50 |  $ICLR | ICON PLC | $7.6M | 0.5% | -28% | — |
| 51 |  $XENE | Xenon Pharmaceuticals Inc. | $7.5M | 0.5% | -44% | 12.9 |
| 52 |  $RVTY | REVVITY, INC. | $7.4M | 0.5% | -48% | 52.4 |
| 53 |  $AGIO | AGIOS PHARMACEUTICALS, INC. | $6.8M | 0.5% | NEW | 26.3 |
| 54 |  $GPCR | Structure Therapeutics Inc. | $6.7M | 0.4% | +8% | — |
| 55 |  $TECH | BIO-TECHNE Corp | $6.6M | 0.4% | -67% | 59.6 |
| 56 |  $GKOS | GLAUKOS Corp | $6.5M | 0.4% | -59% | 39.2 |
| 57 |  $THC | TENET HEALTHCARE CORP | $5.6M | 0.4% | NEW | 66.6 |
| 58 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $5.2M | 0.3% | NEW | 25.4 |
| 59 |  $ISRG | INTUITIVE SURGICAL INC | $5.1M | 0.3% | -38% | 81.4 |
| 60 |  $PRAXPUT | Praxis Precision Medicines, Inc. | $4.8M | — | NEW | — |
| 61 |  $ESPR | Esperion Therapeutics, Inc. | $4.8M | 0.3% | -55% | 34.3 |
| 62 |  $MOH | MOLINA HEALTHCARE, INC. | $4.4M | 0.3% | -28% | 60.5 |
| 63 |  $HQY | HEALTHEQUITY, INC. | $4.3M | 0.3% | -72% | 72.3 |
| 64 |  $BRKR | BRUKER CORP | $4.2M | 0.3% | -85% | 44.9 |
| 65 |  $DAWN | Day One Biopharmaceuticals, Inc. | $3.9M | 0.3% | NEW | 42.6 |
| 66 | — | SPDR SERIES TRUST | $3.8M | — | -70% | — |
| 67 |  $CMPS | COMPASS Pathways plc | $3.7M | 0.3% | NEW | — |
| 68 |  $CNC | CENTENE CORP | $3.7M | 0.2% | -66% | 52.7 |
| 69 |  $GRCE | Grace Therapeutics, Inc. | $3.5M | 0.2% | NEW | — |
| 70 |  $ENGN | enGene Therapeutics Inc. | $3.5M | 0.2% | +12% | — |
| 71 |  $UHSPUT | UNIVERSAL HEALTH SERVICES INC | $3.3M | — | NEW | 71.2 |
| 72 |  $EHAB | Enhabit, Inc. | $3.2M | 0.2% | +4% | 54.8 |
| 73 | — | SELECT SECTOR SPDR TR | $3.1M | — | NEW | — |
| 74 |  $DFTX | Definium Therapeutics, Inc. | $3.0M | 0.2% | NEW | — |
| 75 |  $EQ | Equillium, Inc. | $3.0M | 0.2% | NEW | 27.2 |
| 76 |  $ENSG | ENSIGN GROUP, INC | $3.0M | 0.2% | NEW | 68 |
| 77 |  $IVVD | Invivyd, Inc. | $3.0M | 0.2% | +6% | 25.7 |
| 78 |  $PMVP | PMV Pharmaceuticals, Inc. | $2.9M | 0.2% | NEW | — |
| 79 |  $ALEC | Alector, Inc. | $2.9M | 0.2% | +34% | 8.9 |
| 80 |  $ANRO | Alto Neuroscience, Inc. | $2.8M | 0.2% | NEW | — |
| 81 |  $RLAY | Relay Therapeutics, Inc. | $2.7M | 0.2% | -45% | 12.7 |
| 82 |  $REPL | Replimune Group, Inc. | $2.6M | 0.2% | NEW | — |
| 83 |  $LBRX | LB PHARMACEUTICALS INC | $2.5M | 0.2% | NEW | — |
| 84 |  $LPCN | Lipocine Inc. | $2.4M | 0.2% | NEW | — |
| 85 |  $VIR | Vir Biotechnology, Inc. | $2.2M | 0.1% | NEW | 5.6 |
| 86 |  $AVR | Anteris Technologies Global Corp. | $2.2M | 0.1% | -20% | — |
| 87 |  $AMRN | AMARIN CORP PLC\UK | $2.1M | 0.1% | -14% | 22.6 |
| 88 |  $SVRA | Savara Inc | $2.1M | 0.1% | +126% | — |
| 89 |  $RLMD | RELMADA THERAPEUTICS, INC. | $1.9M | 0.1% | NEW | — |
| 90 |  $CTNM | Contineum Therapeutics, Inc. | $1.9M | 0.1% | +6% | — |
| 91 |  $STRO | SUTRO BIOPHARMA, INC. | $1.8M | 0.1% | -62% | 30.1 |
| 92 |  $INO | INOVIO PHARMACEUTICALS, INC. | $1.8M | 0.1% | NEW | — |
| 93 |  $SRZN | Surrozen, Inc./DE | $1.7M | 0.1% | -38% | — |
| 94 |  $IFRX | InflaRx N.V. | $1.6M | 0.1% | +0% | — |
| 95 |  $KPTI | Karyopharm Therapeutics Inc. | $1.5M | 0.1% | NEW | 20.4 |
| 96 |  $ANAB | ANAPTYSBIO, INC | $1.5M | 0.1% | -78% | 29.4 |
| 97 |  $NVCR | NovoCure Ltd | $1.5M | 0.1% | +12% | — |
| 98 |  $BVS | Bioventus Inc. | $1.5M | 0.1% | -66% | 50 |
| 99 |  $AGL | agilon health, inc. | $1.4M | 0.1% | NEW | 46.9 |
| 100 |  $RARE | Ultragenyx Pharmaceutical Inc. | $1.3M | 0.1% | -80% | 31 |
| 101 |  $EVMN | Evommune, Inc. | $1.3M | 0.1% | NEW | — |
| 102 |  $IMCR | Immunocore Holdings plc | $1.2M | 0.1% | NEW | — |
| 103 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $1.1M | 0.1% | -74% | 26.6 |
| 104 |  $PLRX | PLIANT THERAPEUTICS, INC. | $1.1M | 0.1% | +6% | — |
| 105 |  $SPRY | ARS Pharmaceuticals, Inc. | $1.1M | 0.1% | -46% | 29.7 |
| 106 |  $WHWK | Whitehawk Therapeutics, Inc. | $1.1M | 0.1% | +18% | 9.6 |
| 107 |  $TYRA | Tyra Biosciences, Inc. | $1.0M | 0.1% | -90% | — |
| 108 |  $PASG | Passage BIO, Inc. | $1.0M | 0.1% | +4% | — |
| 109 |  $DHC | DIVERSIFIED HEALTHCARE TRUST | $1.0M | 0.1% | NEW | 39.7 |
| 110 |  $INMD | InMode Ltd. | $926,738 | 0.1% | +9% | — |
| 111 |  $SNDA | SONIDA SENIOR LIVING, INC. | $917,093 | 0.1% | NEW | 34.6 |
| 112 |  $BCYC | BICYCLE THERAPEUTICS PLC | $884,918 | 0.1% | +7% | — |
| 113 |  $EDIT | Editas Medicine, Inc. | $718,570 | 0.1% | +0% | 10.8 |
| 114 |  $SSII | SS Innovations International, Inc. | $550,785 | 0.0% | +46% | 30.8 |
| 115 | $REPLCALL | Replimune Group, Inc. | $397,800 | — | NEW | — |
| 116 |  $RVP | RETRACTABLE TECHNOLOGIES INC | $384,278 | 0.0% | +0% | 22.2 |
| 117 |  $EHTH | eHealth, Inc. | $284,980 | 0.0% | -1% | 35.5 |
| 118 |  $SLQT | SelectQuote, Inc. | $225,148 | 0.0% | +0% | 64.2 |
| 119 |  $AIRS | Airsculpt Technologies, Inc. | $209,813 | 0.0% | NEW | 24.3 |
| 120 | $KPTICALL | Karyopharm Therapeutics Inc. | $132,566 | — | NEW | 20.4 |
New Positions (42)
$VRTXCALL VERTEX PHARMACEUTICALS INC / MA$40.2M$WELL WELLTOWER INC.$35.8M$DOC HEALTHPEAK PROPERTIES, INC.$32.5M$OHI OMEGA HEALTHCARE INVESTORS INC$25.7M$QGEN QIAGEN N.V.$21.8M$QGENCALL QIAGEN N.V.$19.1M$INSMCALL INSMED Inc$15.4M$RGEN REPLIGEN CORP$14.2M$LTC LTC PROPERTIES INC$11.9M$CHE CHEMED CORP$11.7M$UNHCALL UNITEDHEALTH GROUP INC$10.8M$VKTX Viking Therapeutics, Inc.$7.8M$AGIO AGIOS PHARMACEUTICALS, INC.$6.8M$THC TENET HEALTHCARE CORP$5.6MExited Positions (31)
$DHR DANAHER CORP /DE/
$EXK ENDEAVOUR SILVER CORP
$TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD$UNH UNITEDHEALTH GROUP INC
$BIIB BIOGEN INC.
$SEM SELECT MEDICAL HOLDINGS CORP
$CGON CG Oncology, Inc.
$BMY BRISTOL MYERS SQUIBB CO
$ELV Elevance Health, Inc.
$MNKD MANNKIND CORP
$ASND Ascendis Pharma A/S
$ILMN ILLUMINA, INC.
$DVAX DYNAVAX TECHNOLOGIES CORP
$EWTX Edgewise Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Eversept Partners, LP including:
Track Eversept Partners, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Eversept Partners, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Eversept Partners, LP
13F Pro is an AI hedge fund tracker and stock research platform. For Eversept Partners, LP (SEC CIK: 1697013), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Eversept Partners, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.